Newark-based ANP Technologies Inc. received Emergency Use Authorization for its rapid Covid-19 test from the Food and Drug Administration,
The test, which provides a visible result in 15 minutes, is based on ANP’s technology.
The test is sensitive in the detection of nasal swab specimens. In addition to its 95% detection rate during clinical testing, ANP’s test has also been demonstrated to be effective at detecting variants, including Delta, a release stated.
“The NIDS Covid-19 Antigen Rapid Test was developed using our NIDS technology platform that was initially developed for the rapid detection of various biological warfare agents for the U.S. military more than a decade ago,” says Dr. Ray Yin, president, and CTO of ANP. “With the Covid-19 pandemic, ANP quickly configured its NIDS platform for the detection of SARS-CoV-2 antigen and achieved outstanding performance under the funding from the Department of Defense and the RADx initiative.”
“With this pivotal FDA authorization, ANP is now focusing on the large-scale production of the test kits and welcomes all partnerships and collaborations to improve testing production capacity and speed to market which is paramount to get folks back to work/school and reopen the economy,” said Greg Witham, senior director of Business Development and Contracts at ANP.
This project was funded in part by the National Institutes of Health Rapid Acceleration of Diagnostics Iinitiative with federal funds from the National Institute of Biomedical Imaging and Bioengineering, National Institutes of Health.
, the current contract is funded from the Public Health and Social Services Emergency Fund through the Biomedical Advanced Research and Development Authority, HHS Office of the Assistant Secretary for Preparedness and Response, Department of Health and Human ServicesANP has supplied tests for the detection of various biological agents to the Department of Defense in the past 15 years.
